Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana K Orsini

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|February 28, 2026
Progress, potential and pitfalls of ketamine as a treatment for Depression and related disordersDiana K Orsini, Sara Di Luch, Gabrielle F M Lovell, et al.
Psychiatry Research|August 20, 2025
Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorderSipan Haikazian, Roger S McIntyre, Shakila Meshkat, et al.
Journal of Psychopharmacology (Oxford, England)|June 24, 2026
Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic reviewShreya Vasudeva, Gabrielle F M Lovell, Sabrina Wong, et al.
Clinical Pharmacology and Therapeutics|May 28, 2026
The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of DepressionGia Han Le, Sabrina Wong, Danica E Johnson, et al.
General Hospital Psychiatry|April 21, 2026
Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic reviewGabrielle F M Lovell, Shreya Vasudeva, Diana K Orsini, et al.
The Lancet. Psychiatry|April 17, 2026
Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatryJoseph J Taylor, Balázs Szigeti, Noah D Silverberg, et al.
JAMA Psychiatry|April 15, 2026
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic ReviewDiana K Orsini, Sabrina Wong, Sara Di Luch, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|February 28, 2026
Progress, potential and pitfalls of ketamine as a treatment for Depression and related disordersDiana K Orsini, Sara Di Luch, Gabrielle F M Lovell, et al.
Psychiatry Research|August 20, 2025
Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorderSipan Haikazian, Roger S McIntyre, Shakila Meshkat, et al.
Journal of Psychopharmacology (Oxford, England)|June 24, 2026
Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic reviewShreya Vasudeva, Gabrielle F M Lovell, Sabrina Wong, et al.
Clinical Pharmacology and Therapeutics|May 28, 2026
The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of DepressionGia Han Le, Sabrina Wong, Danica E Johnson, et al.
General Hospital Psychiatry|April 21, 2026
Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic reviewGabrielle F M Lovell, Shreya Vasudeva, Diana K Orsini, et al.
The Lancet. Psychiatry|April 17, 2026
Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatryJoseph J Taylor, Balázs Szigeti, Noah D Silverberg, et al.
JAMA Psychiatry|April 15, 2026
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic ReviewDiana K Orsini, Sabrina Wong, Sara Di Luch, et al.
Pageof 1